Good results from the combo p2b will lead to a phase 3 registration trial and designed for accelerated approval according to their latest investor pack. T-Vec trial was a phase 3 trial with nearly 300 people but if response rates are as good or better than T-Vec in a larger study with barely any side affects I think that Oncosec would deserve a much larger market cap than 30 million. Maybe this takes another 2 years but in the end this is heading in the right direction.
News 
Market Data 
Discover 
AI
